Chia C. Portera

500 total citations
19 papers, 385 citations indexed

About

Chia C. Portera is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chia C. Portera has authored 19 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chia C. Portera's work include HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (7 papers) and Cell death mechanisms and regulation (3 papers). Chia C. Portera is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (7 papers) and Cell death mechanisms and regulation (3 papers). Chia C. Portera collaborates with scholars based in United States, India and United Kingdom. Chia C. Portera's co-authors include Stephanie Royer‐Joo, Sandra M. Swain, Sherry X. Yang, Catherine K. Chow, Arlene Berman, Janice M. Walshe, Neelima Denduluri, Douglas R. Rosing, Diana Nguyen and Avi Ashkenazi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Chia C. Portera

19 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chia C. Portera United States	10	234	195	105	60	51	19	385
Nicolas Frances Switzerland	11	191 0.8×	221 1.1×	63 0.6×	33 0.6×	71 1.4×	22	436
Viola Regondi Italy	8	226 1.0×	262 1.3×	40 0.4×	91 1.5×	157 3.1×	17	466
Nicola Cresti United Kingdom	13	331 1.4×	216 1.1×	54 0.5×	51 0.8×	83 1.6×	34	639
Laeeq Malik Australia	12	192 0.8×	245 1.3×	27 0.3×	76 1.3×	73 1.4×	30	460
Ivan Potapenko Denmark	10	61 0.3×	252 1.3×	141 1.3×	76 1.3×	73 1.4×	16	475
Sadie Whittaker United States	9	202 0.9×	258 1.3×	46 0.4×	77 1.3×	42 0.8×	12	483
Tracy Lessor United States	8	219 0.9×	289 1.5×	65 0.6×	177 3.0×	25 0.5×	8	533
C.P. Schröder Netherlands	9	179 0.8×	90 0.5×	138 1.3×	24 0.4×	57 1.1×	17	377
Silvia Marchetti Italy	8	242 1.0×	52 0.3×	88 0.8×	35 0.6×	34 0.7×	25	402
Bei Wang United States	10	261 1.1×	66 0.3×	219 2.1×	47 0.8×	15 0.3×	32	349

Countries citing papers authored by Chia C. Portera

Since Specialization

Citations

This map shows the geographic impact of Chia C. Portera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chia C. Portera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chia C. Portera more than expected).

Fields of papers citing papers by Chia C. Portera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chia C. Portera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chia C. Portera. The network helps show where Chia C. Portera may publish in the future.

Co-authorship network of co-authors of Chia C. Portera

This figure shows the co-authorship network connecting the top 25 collaborators of Chia C. Portera. A scholar is included among the top collaborators of Chia C. Portera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chia C. Portera. Chia C. Portera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Heras, Begoña de las, Kamal S. Saini, Frances Boyle, et al.. (2020). Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months. SHILAP Revista de lepidopterología. 8(2). 171–182. 21 indexed citations

Swain, SM, Andreas Schneeweiß, Lorenzo Gianni, et al.. (2016). Abstract P4-14-14: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Cancer Research. 76(4_Supplement). P4–14. 2 indexed citations

Tolcher, Anthony W., Johanna C. Bendell, Kyriakos P. Papadopoulos, et al.. (2016). A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors. Clinical Cancer Research. 22(18). 4567–4573. 26 indexed citations

Robert, N. J., et al.. (2016). Abstract P4-14-13: Pertuzumab (P) use in first-line HER2-positive metastatic breast cancer (mBC) in US community oncology practices: Treatment patterns and outcomes. Cancer Research. 76(4_Supplement). P4–14. 4 indexed citations

Miles, David, et al.. (2015). Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.. Journal of Clinical Oncology. 33(15_suppl). 598–598. 5 indexed citations

Robert, Nicholas J., Hans‐Peter Goertz, Lina Asmar, et al.. (2015). 1868 Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer (MBC) treated with pertuzumab (P) in the first-line in a real-world setting. European Journal of Cancer. 51. S288–S288. 1 indexed citations

Babigumira, Joseph B., Vincent Antao, Bruce Wang, et al.. (2014). Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer.. Journal of Clinical Oncology. 32(15_suppl). 642–642. 4 indexed citations

Wong, Harvey, Stephen E. Gould, Nageshwar Budha, et al.. (2013). Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist. Drug Metabolism and Disposition. 41(12). 2104–2113. 42 indexed citations

Lim, Bora, Niraj J. Gusani, Nabeel Sarwani, et al.. (2013). FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biology & Therapy. 14(8). 711–719. 12 indexed citations

10.

Wainberg, Zev A., Wells A. Messersmith, Parvin F. Peddi, et al.. (2013). A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 12(4). 248–254. 50 indexed citations

11.

Tolcher, Anthony W., Kyriakos P. Papadopoulos, Amita Patnaik, et al.. (2013). Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.. Journal of Clinical Oncology. 31(15_suppl). 2503–2503. 13 indexed citations

12.

Lima, Caio M. Rocha, Soley Bayraktar, Jessica MacIntyre, et al.. (2012). Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Cancer Investigation. 30(10). 727–731. 33 indexed citations

13.

Bendell, Johanna C., Mark Kozloff, Amy V. Kapp, et al.. (2012). Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(15_suppl). 3543–3543. 13 indexed citations

14.

Levine, Paul H., Chia C. Portera, Heather J. Hoffman, et al.. (2012). Evaluation of Lymphangiogenic Factors, Vascular Endothelial Growth Factor D and E-Cadherin in Distinguishing Inflammatory From Locally Advanced Breast Cancer. Clinical Breast Cancer. 12(4). 232–239. 13 indexed citations

15.

Kozloff, Mark, Wells A. Messersmith, Amy V. Kapp, et al.. (2012). Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(15_suppl). 3552–3552. 7 indexed citations

16.

Baron, Ari David, Cindy L. O’Bryant, Youngnim Choi, Stephanie Royer‐Joo, & Chia C. Portera. (2011). Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 29(4_suppl). 532–532. 8 indexed citations

17.

Portera, Chia C., Janice M. Walshe, Douglas R. Rosing, et al.. (2008). Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Clinical Cancer Research. 14(9). 2710–2716. 125 indexed citations

18.

Portera, Chia C., Janice M. Walshe, Neelima Denduluri, et al.. (2007). A report of cardiac events in a phase II clinical study using trastuzumab combined with pertuzumab in HER2-positive metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). 1028–1028. 3 indexed citations

19.

Raddino, Riccardo, Giovanna Pelà, Daniela Uberti, et al.. (2001). Estrogen derivative relaxes rabbit aorta via the endothelial receptor system.. PubMed. 2(1). 49–54. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact